Product Description
Levocarnitine is used to prevent and treat a lack of carnitine. It is used to prevent and treat this condition in patients with kidney disease on dialysis. It is given to people whose body cannot properly use carnitine from their diet. Lack of carnitine can lead to liver, heart, and muscle problems. (Sourced from: https://www.mayoclinic.org/drugs-supplements/levocarnitine-oral-route-intravenous-route/description/drg-20064527)
Mechanisms of Action: CPT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | India | Israel | Italy | Japan | Jordan | Korea | Luxembourg | Malta | Mexico | Netherlands | Peru | Philippines | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sigma Tau
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Kidney Diseases
Phase 2: Cardio-Renal Syndrome|Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PURE | P2 |
Not yet recruiting |
Heart Failure|Kidney Diseases|Cardio-Renal Syndrome |
2025-11-01 |
24% |
| IP-001-21 | P3 |
Unknown Status |
Kidney Diseases |
2024-12-31 |
|
| ASTRA | P3 |
Active, not recruiting |
Kidney Diseases |
2023-11-14 |
|
| ND | P2 |
Active, not recruiting |
Unknown |
2011-09-23 |